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Abstract
Hyperglycemia, which reduces the efficacy of treatments and worsens clinical outcomes, is
common in stroke. Ability of pregabalin to reduce neuroexcitotoxicity may provide protection
against stroke, even under hyperglycemia. We investigated its protective effect against
hyperglycemic stroke and its possible molecular mechanisms. Male Wistar rats adminis-
tered dextrose to cause hyperglycemia, underwent middle cerebral artery occlusion for 1 h
and subsequent reperfusion. Rats were treated with an intraperitoneal injection of 30 mg/kg
pregabalin or an equal amount of normal saline at the onset of reperfusion (n = 16 per
group). At 24 h after reperfusion, neurological deficit, infarct volume, and apoptotic cell
count were assessed. Western blot analysis was performed to determine protein expression
of high-mobility group box 1 (HMGB1), toll-like receptor-4 (TLR-4), phosphorylated nuclear
factor-kappa B (p-NF-κB), interleukin-1beta (IL-1β), tumor necrosis factor-alpha (TNF-α),
phosphorylated inducible and endothelial nitric oxide synthase (p-iNOS, p-eNOS), Bcl-2,
Bax, Cytochrome C, and caspase-3 in the brain. Pregabalin-treated rats showed signifi-
cantly improved neurological function (31% decrease in score), reduced infarct size (by
33%), fewer apoptotic cells (by 63%), and lower expression levels of HMGB1, TLR4, p-NF-
κB, IL-1β, and TNF- α, compared with control rats. Decreased p-iNOS and increased p-
eNOS expressions were also observed. Expression of Bax, Cytochrome C, and cleaved
caspase-3/caspase3 was significantly downregulated, while Bcl-2 expression was
increased by pregabalin treatment. Pregabalin administration upon reperfusion decreased
neuronal death and improved neurological function in hyperglycemic stroke rats. Cogent
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Introduction
Irrespective of a history of diabetes, approximately 30–40% of patients that present with acute
ischemic stroke exhibit hyperglycemia, which is known to exacerbate clinical outcomes [1].
Unfortunately, the application of intensive glycemic control does not improve outcomes leav-
ing clinicians with an additional burden, whilst already being confronted with limited thera-
peutic options against stroke in general [2, 3].
The adverse influence of acute hyperglycemia has also been confirmed in animal models of
middle cerebral artery occlusion (MCAO) [4]. After energy depletion, ischemic injury univer-
sally starts with presynaptic neuronal discharge leading to activation of voltage-gated calcium
channels (VGCC) and release of excitatory neurotransmitters in the ischemic core [5].
This excitotoxicity is followed by delayed inflammatory responses in the penumbra, with
high-mobility group box 1 (HMGB1) recently identified as the key pro-inflammatory molecule
linking these two successive events [6]. In the context of acute hyperglycemia, accumulating
evidence suggests that intensification of these pathologic processes leads to increased cerebral
injury [7–9]. In addition, hyperglycemia has also been shown to abolish the experimentally
proven protective effects of certain agents, such as volatile anesthetic, against cerebral ische-
mia-reperfusion (I-R) injury [10, 11].
The excitotoxicity persists for hours, even after reperfusion, providing an estimated thera-
peutic window of up to 10–12 hours [12]. Therefore, we hypothesized that therapies aimed at
this initial event would successfully ameliorate its downstream complex biochemical events
leading to neuronal loss, and retain their protective effects against cerebral I-R injury even in
acute hyperglycemic condition.
Pregabalin, a widely used drug for neuropathic pain, robustly binds to the α2-δ subunit of
the VGCC reducing Ca2+ influx and release of excitotoxic neurotransmitters at presynaptic
nerve endings [13]. Pregabalin’s neuroprotective effect has been evaluated in terms of spinal
cord injury [14] and cerebral I-R injury induced by deep hypothermic circulatory arrest [15]
or normoglycemic MCAO [16] providing promising results. However, evidence regarding its
neuroprotective effects and related mechanisms against stroke is lacking in the context of
hyperglycemia, which deserves a high priority considering its prevalence and clinical impact
on the outcome.
Therefore, the aim of this present study was to investigate the neuroprotective effects of
pregabalin in a rat model of hyperglycemic stroke and its related key molecular mechanisms
associated with HMGB1.
Materials and methods
Animal preparation
All animal procedures were approved by the committee for the Care and Use of Laboratory
Animals, Yonsei University College of Medicine, and were performed in accordance with the
Guide for the Care and Use of Laboratory Animals published by the US National Institutes of
Health. Rats were fasted except for water for 8 h before surgery, and allowed free access to food
and water after surgery. All rats received dextrose (1.2 g/kg) 1 h before MCAO via the tail vein.
A blood glucose concentration >11.1 mmol/L was considered as hyperglycemia [17]. The
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blood glucose concentration was determined at baseline, before MCAO, upon reperfusion,
and 24 h thereafter.
MCAO models and study groups
Male Wistar rats (8–10 wk old) weighing 270–300 g were anesthetised with xylazine (Rompun,
Vial Korea, 10 mg/kg) and tiletamine/zolazepam (Zoletil 50, Virbac Korea, 30 mg/kg). To min-
imize potential suffering from the procedure, supplemental analgesia with local lidocaine infil-
tration was provided if there was sudden movement or changes in vital sign of animals. The
tail artery was cannulated to monitor mean arterial pressure (MAP) and collect blood. The
heart rate (HR) was monitored by subcutaneous stainless steel electrodes connected to the
power lab system (ML845 PowerLab with ML132; AD Instruments, Colorado Springs, CO).
The body temperature was continuously monitored and maintained around 37˚C using a heat-
ing pad.
The experimental MCAO model was generated as previously described by Longa et al. [18].
Briefly, the left common carotid artery (CCA), external carotid artery (ECA), and internal
carotid artery (ICA) were exposed through a midline neck incision. The ECA was dissected
further distally and coagulated along with the terminal lingual and maxillary artery branches,
which were then divided. A 4–0 monofilament suture (Doccol Corporation, MA, USA) with
silicone rubber coated-rounded head was inserted through the proximal ECA stump into the
ICA. After 60 minutes of occlusion, the suture was withdrawn, and the skin was sutured with
an infiltration of 0.5% bupivacaine for analgesia. For sham operations, all procedures were
identical except that the suture was not inserted.
The rats were randomly assigned to three groups: 1) Hyperglycemia-Sham group (n = 8),
normal saline 2 ml intraperitoneally (IP) after 60 min of ICA exposure without MCAO; 2)
Hyperglycemia-untreated MCAO control group (n = 16), normal saline 2 ml IP after 60 min
of MCAO, followed by reperfusion, 3) Hyperglycemia-pregabalin treated MCAO group
(n = 16), pregabalin 30 mg/kg in normal saline 2 ml IP after 60 min of MCAO, followed by
reperfusion. The dose of pregabalin was selected from previous studies of spinal cord injury
and deep hypothermic circulatory arrest [14, 15], and also from our preliminary study, in
which rats treated with 30 mg/kg demonstrated a smaller infarct size, better neurological func-
tion, and lower apoptotic cell count than those treated with 10 mg/kg (Fig 1). The comparative
dose of 10 mg/kg was selected from the previous MCAO study in mice under normoglycemia
[16]. The dose of 30 mg/kg was chosen for all subsequent experiments. Physical condition of
all experimental animals were monitored throughout the procedure and then, every 12 h until
the euthanasia was performed with IP injection of an overdose (60mg/kg) of sodium pentobar-
bital. None of the animals became ill or die prior to the experimental endpoint.
Neurological deficits
Neurobehavioral assessment was performed assessing four different functions (general status,
simple motor deficit, complex motor deficit, and sensory deficit) by combining elements from
several previously described scoring systems [19]. The score given in each test (by a researcher
blinded to the treatment group) was the sum of all four individual scores: 0 (best)– 48 (worst)
score.
Evaluation of infarct size
At the end of 24 h reperfusion, brains were then perfusion-fixed and 2 mm coronal sections
were cut with a tissue cutter. The infarct area of the brain section was determined using 2%
2,3,5-triphenyltetrazolium chloride staining as described previously [16]. The borders of the
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infarct in each brain slice were outlined and the area quantified using Image J software. For
each brain section, the infarct volume was calculated by subtracting the area of the non-
infarcted ipsilateral hemisphere from that of the intact contralateral hemisphere. The percent-
age of infarct volume was determined by dividing the sum for the area of infarction by the
total of that of contralateral hemisphere to avoid the influence of edema [20].
TUNEL assay
The detection of apoptosis on brain paraffin sections was evaluated using the terminal deoxy-
nucleotidyl transferase-mediated dUTP nick-end labeling (TUNEL) staining according to the
manufacturer’s instructions (Roche Diagnostics). The number of TUNEL-positive cells was
counted in the cortex and the striatum by an observer blinded to the treatment groups using
an Olympus microscope at ×400.
Immunoblot analysis
The tissue samples from the striatum and cortex of the ipsilateral hemisphere were homoge-
nized in a buffer consisting of 20 mM Tris (pH 7.5), 150 mM NaCl, 1% Triton, 1 mM
Fig 1. Determination of the dose range for pregabalin treatment. Rats were treated with the indicated
dose (mg/kg) of pregabalin (PGB). Representative pictures of TTC-stained brain sections from rat in the
different group (a); Infarct volumes expressed as a percentage of area at risk (b); Neurological deficit scores
(c). Values are mean ± SD from 8 independent rats. *P <0.05. Scale bar: 1 cm.
doi:10.1371/journal.pone.0171147.g001
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Na2EDTA, 1 mM EGTA, 2.5 mM sodium pyrophosphate, and protease inhibitors. Equal
amounts of total protein from each group underwent immunoblotting assays. Proteins were
separated on sodium dodecyl sulfate-polyacrylamide gel electrophoresis, and immunoblotting
with anti-HMGB1, anti-phospho-inducible nitric oxide synthase (iNOS), anti-iNOS, anti-
phospho-endothelial NOS (eNOS), anti-eNOS (Abcam, Cambridge), anti-Toll-like receptor-4
(TLR-4), anti-Actin (Santa Cruz, CA), anti-Bcl-2, anti-Bax, anti-cytochrome C, anti-cleaved
caspase-3, anti-caspase-3, anti-phospho-nuclear factor-kappa B (NF-κB), and anti-NF-κB, (all
Cell Signaling Technology, Beverly, MA) was performed at least three times each.
Statistical analysis
All results are expressed as mean (SD). Serum glucose concentrations were analyzed using a
repeated-measures analysis of variance (ANOVA). Other variables were analyzed using a two-
way ANOVA. The P-values of post hoc tests were adjusted using Bonferroni’s method. Values
of P<0.05 were considered statistically significant.
Results
Pregabalin treatment conveyed both functional and histological
neuroprotection against hyperglycemic MCAO/reperfusion
Dextrose administration increased blood glucose concentrations >11.1 mmol/L until 24 h
after reperfusion in all rats without any intergroup differences (S1 Fig). Hemodynamic data,
including MAP and HR, also showed no intergroup differences (data not shown). No infarc-
tions were observed in the sham group, while extensive infarct lesions developed in the stria-
tum and lateral cortex of the control group. Compared with the control group, the infarct
volume was significantly reduced in all rats in the pregabalin (30 mg/kg) group [38.4 ± 5.5%
vs. 25.9 ± 3.5%, P <0.05] (Fig 1a and 1b). The neurologic deficit score of the pregabalin group
was significantly lower (better) compared with the control group [11 ± 3 vs. 16 ± 3, P <0.05]
(Fig 1c). There were more TUNEL-positive apoptotic cells in the penumbra cortex of the con-
trol group than in the pregabalin group [63.9 ± 5.6% vs. 23.8 ± 6.1%, P<0.05] (Fig 2).
Pregabalin treatment attenuated expressions of HMGB1/TLR-4/p-NF-κB
and pro-inflammatory cytokines in the brain tissue
The expression level of HMGB1 was comparable between the sham group and the pregabalin
group. Compared to that, it was significantly higher in the control group. Expression of TLR-4
was significantly increased in both the control and pregabalin groups compared with that in
the sham group, while it was significantly lower in the pregabalin group than in the control
group. Expression of p-NF-κB was significantly increased in both the control and pregabalin
groups compared with that in the sham group, while it was significantly lower in the pregaba-
lin group than in the control group (Fig 3). Compared with the sham group, expressions of IL-
1β and TNF-α were significantly increased both in the control and pregabalin groups. Their
expression levels were significantly lower in the pregabalin group than in the control group.
Pregabalin treatment decreased expression of p-iNOS and retained
expression of p-eNOS in the brain tissue
The expression of p-iNOS could only be weakly detected in the sham group while it was signif-
icantly upregulated both in the control and pregabalin groups compared with that in the sham
group. Its expression was significantly blunted in the pregabalin group compared with that in
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the control group. Levels of p-eNOS were decreased in the control group compared with those
in the sham group, while its expression was retained in the pregabalin group (Fig 4).
Pregabalin treatment favorably modulated expressions of Bcl-2, Bax,
cytochrome C, and caspase-3 in the brain tissue
Compared with the sham group, both the control and pregabalin groups exhibited a significant
reduction in Bcl-2 expression, while it was significantly higher in the pregabalin group than in
the control group. On the contrary, expressions of Bax and cytochrome C were significantly
increased in both the control and pregabalin groups compared with those in the sham group,
while their increases were significantly smaller in the pregabalin group compared with those in
the control group (Fig 5a). With regard to cleaved caspase-3, its protein expression level was
Fig 2. Effect of pregabalin treatment upon reperfusion on apoptosis in the brain of hyperglycemic
stroke rat. Pregabalin reduced the number of TUNEL-positive cells compared with the control group.
Quantitative representation of TUNEL-positive cells was determined by random counting of four fields per
section. Values are mean ± SD from 8 independent rats. *P <0.05. Scale bar: 50 μm.
doi:10.1371/journal.pone.0171147.g002
Fig 3. Pregabalin treatment attenuated expressions of HMGB1/TLR-4/p-NF-κB/IL-1β and TNF-α in the
brain of hyperglycemic stroke rat. The protein levels of HMGB1, TLR-4, P-NF-kB, NF-kB, IL-1β and TNF-ɑ
were detected in the ipsilateral hemisphere of rat brain in each group using western blot analysis. Right panels
were quantified signal by scanning densitometry. Values are mean ± SD from 5 independent rats. *P <0.05.
doi:10.1371/journal.pone.0171147.g003
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Fig 4. Pregabalin treatment favorably modulated expressions of NOS in the brain of hyperglycemic
stroke rat. The western blot analysis performed. The protein levels of P-iNOS and iNOS were detected in the
ipsilateral hemisphere of rat brain in each group. Right panel was quantified signal by scanning densitometry.
Values are mean ± SD from 5 independent rats. *P <0.05.
doi:10.1371/journal.pone.0171147.g004
Fig 5. Pregabalin treatment favorably modulated expressions of apoptosis-related molecules in the
brain of hyperglycemic stroke rat. The protein levels of Bcl-2, Bax, Cytochrome C (a), Cleaved caspase-3
and Caspase-3 (b) were detected in the ipsilateral hemisphere of rat brain in each group using western blot
analysis. Right panels were quantified signal by scanning densitometry. Values are mean ± SD from 5
independent rats. *P <0.05.
doi:10.1371/journal.pone.0171147.g005
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also significantly increased in both the control and pregabalin groups than in the sham group,
while the increase was significantly smaller in the pregabalin group than in the control group
(Fig 5b).
Discussion
In the present study, we observed the functional and histological neuroprotective effects of
pregabalin administration upon reperfusion after 1 h of MCAO in a rat model of hyperglyce-
mic stroke. It reduced infarct size by 33%, improved neurological deficits (31% decrease in
score), presented with fewer apoptotic cells (by 63%), and demonstrated favorable expression
of apoptosis-regulatory molecules in the brain tissue. Activation of HMGB1/TLR-4 signaling
and NF-κB-mediated pro-inflammatory cascades was attenuated by pregabalin treatment.
Favorable modulation of NOS isoforms was also revealed.
Hyperglycemia has been observed to be present in one-third of all ischemic stroke patients
and is known to be associated with poorer prognosis regardless of diabetes history [1]. Of
note, a previous meta-analysis reported even higher mortality of stroke in non-diabetic hyper-
glycemic patients compared with pre-existing diabetic patients [21]. In conjunction, experi-
mental studies have revealed that hyperglycemia exacerbates metabolic deterioration,
intensifies the inflammatory response and oxidative stress, augments blood-brain barrier
(BBB) disruption, and lowers the availability of NO, leading to increased infarct volume,
edema, and hemorrhagic transformation [7, 8, 22, 23]. Even worse, several therapeutic modali-
ties that have shown consistent efficacy in animal studies including the volatile anesthetic post-
conditioning lost their neuroprotective effects or even enhanced cerebral damage in hypergly-
cemic states [10, 11]. The results of intensive glycemic control in an attempt to attenuate
exacerbation of stroke have also been largely disappointing [2, 3].
One of the most prominent and initial metabolic issues related to ischemic stroke is dis-
tressed Ca2+ homeostasis and bursts of excitatory amino acids, which ultimately result in neu-
ronal cell death [5]. Several N-methyl-D-aspartate (NMDA) receptor antagonists and calcium
channel blockers (mostly L-type) have shown protective effects against stroke-related damage
in a number of experimental models [24]. However, few of them have achieved successful clin-
ical translations mainly because of their adverse psychotomimetic side effects or unwanted
influence on the systemic vasculature lowering the perfusion pressure [25, 26]. In consider-
ation of the exaggerated Ca2+ imbalance and neuronal excitability [7], hyperglycemic patients
may require even higher doses, which may not become applicable on account of these safety
issues.
By binding to VGCC, pregabalin suppresses Ca2+ influx and has an effect more upstream of
the neuronal excitotoxicity, thus blocking the release of not only glutamate but also other excit-
atory amino acids and providing more comprehensive coverage compared with NMDA antag-
onists [13]. Indeed, its protective effects have already been demonstrated in experimental
models of normoglycemic MCAO and deep hypothermic circulatory arrest with cardiopulmo-
nary bypass [15,16]. Thus, we hypothesized that blocking this initial insult, neuroexcitotoxicity,
may ameliorate its downstream events leading to neuronal death and convey neuroprotection
against ischemic stroke, even under hyperglycemic condition.
We found in the current hyperglycemic stroke experiment that pregabalin has potent anti-
inflammatory properties via downregulation of the HMGB1/TLR-4 signaling pathway and
attenuation of p-NF-κB expression. HMGB1, a ubiquitous non-histone nuclear protein, is a
key mediator of the immune mechanism in stroke. After extracellular release early after ische-
mia, it activates immune cells and induces inflammatory cytokine expression via binding to
cell surface receptors even hours to days after reperfusion in the ischemic penumbra [6].
Effect of pregabalin on hyperglycemic stroke
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Hyperglycemia enhances extracellular release of HMGB1, which has been demonstrated as an
important mechanism for worsened ischemic damage [9]. Expressions of its receptors impli-
cated in stroke, including TLRs, have also been demonstrated to be increased by hyperglyce-
mia [27]. Of note, experimental evidences indicate that HMGB1 may participate in further
excitotoxicity in the penumbra after stroke by stimulating NMDA receptors and the release of
excitatory amino acids [28, 29]. It is likely that pregabalin may have sufficient protective capac-
ity to interrupt such a continuous damaging process in the hyperglycemic states.
One of the most detrimental effects of hyperglycemia in stroke is the more pronounced
decrease in blood flow in the penumbra related to NO dysfunction, which may persist late into
reperfusion [30]. eNOS activity is critical in maintaining adequate tissue perfusion and BBB
integrity under central nervous system (CNS) trauma or inflammation, as well as ischemic
stroke [31, 32]. Accordingly, eNOS knockout mice exhibited larger infarction following ische-
mic stroke [33]. Hyperglycemia has been shown to decrease the activity of eNOS through
downregulation of the phosphatidylinositol 3-kinase/Akt pathway [34]. In the present study,
pregabalin preserved eNOS activity in hyperglycemic stroke rats, which might also have played
a role in its neuroprotective effects.
On the other hand, we observed decreased phosphorylation of iNOS following pregabalin
treatment. iNOS has been regarded as a major contributor to the initiation and exacerbation
of inflammatory and degenerative conditions of the CNS [35]. It has been associated with
superoxide and peroxynitrite generation and nitrosylation of mitochondrial metabolic
enzymes, leading to neuronal cell death [35, 36]. The essential molecule for the gene transcrip-
tion and mRNA stability of iNOS during stroke is NF-κB, which is activated by oxidative
stress, glutamate, pro-inflammatory cytokines, and by hyperglycemia per se [37]. Downregula-
tion of iNOS in our hyperglycemic stroke rats by pregabalin might have been attributable to
inhibition of the NF-κB transcription pathway, cytokine production, and oxidative stress.
Although complexly interrelated, the overall hierarchy of neuronal injury after oxygen dep-
rivation starts with excitotoxicity and necrosis, which triggers an inflammatory response that
causes further neuronal loss by apoptosis [5]. An important downstream mediator of the
neuro-excitotoxicity linked with inflammation was found to be HMGB1, which subsequently
influences a well-known key inflammatory regulator, NF-κB [6]. In that context, our results
provide primary evidence that blocking the foremost and universal event after neuronal energy
depletion, excitotoxicity, with pregabalin may improve outcome after ischemic stroke under
hyperglycemic conditions. The current study confirms that pregabalin’s beneficial influences
are present in all of the above mentioned key inflammatory regulators, NOS, and the anti-apo-
ptotic pathways of neuronal cell death after I-R. An additional strength of the current study is
that it firstly addressed the neuroprotective effect of a drug with known clinical safety and reli-
able pharmacokinetics [38] against hyperglycemic stroke. Considering the high prevalence of
hyperglycemia with stroke and its indisputable association with adverse outcome while hinder-
ing potentially effective treatments, our results should be of clinical relevance that merits fur-
ther clinical trials.
This study is subject to the following limitations. First, we cannot draw any conclusion
regarding the potential direct influence of pregabalin on each of the specific downstream path-
ways of neuronal cell death as there are no specific antagonists to pregabalin and it blocks
more than just the release of glutamate, including other excitatory neurotransmitters. Second,
we did not make any direct comparisons with normoglycemic conditions as they were already
reported in a previous study of a mouse MCAO model, which indirectly investigated its cal-
cium-related mechanisms [16]. In that study, although not completely identical in terms of the
methods, pregabalin resulted in up to 70% reduction in infarct size as opposed to 33% in our
study implicating the adverse influence of hyperglycemia. Moreover, mechanisms for
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hyperglycemia-induced exacerbation of the stroke pathophysiology including excitotoxicity
and HMGB1 cascades have been already well established [7–9, 22, 23]. While avoiding redun-
dancies, we have provided evidence that neuroprotection against stroke can be achieved in the
hyperglycemic states in which existing therapeutic modalities have lost their efficacies [39, 40].
Third, although we could clearly delineate pregabalin’s neuroprotective effects at 24 h after
reperfusion, delayed neurologic injury may further ensue 24–72 h after reperfusion, which
merits a further study.
Conclusions
Pregabalin administration upon reperfusion conveyed significant functional and histological
neuroprotection after 1 h of MCAO under hyperglycemia. These beneficial influences were
observed to be associated with major regulators of inflammation, HMGB1, and subsequently,
NF-κB and anti-apoptotic pathways, as well as NOS.
Supporting information
S1 Fig. Time course of blood glucose concentrations. MCAO = middle cerebral artery occlu-
sion; PGB = pregabalin group. Values are mmol/L and expressed as mean ± SD. P <0.05
compared with the baseline in each group.
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